These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
123 related articles for article (PubMed ID: 10800440)
1. [Intravenous perfluorocarbons: 30 years of research--what now?]. Max M; Roissant R Dtsch Med Wochenschr; 2000 Apr; 125(15):444. PubMed ID: 10800440 [No Abstract] [Full Text] [Related]
2. [Intravenous perfluorocarbons. Artificial oxygen carriers and their medical applications]. Frietsch T; Lenz C; Waschke KF Dtsch Med Wochenschr; 2000 Apr; 125(15):465-72. PubMed ID: 10800445 [No Abstract] [Full Text] [Related]
3. [Changes in the microcirculation in traumatic-hemorrhagic shock following therapy with blood substitutes based on perfluorocarbons]. Kretschmar KH; Hoffmann G; Reichelt H Z Med Lab Diagn; 1989; 30(1):56-7. PubMed ID: 2718581 [No Abstract] [Full Text] [Related]
4. Clinical potential of intravenously administered perfluorocarbons. Habler O; Kleen M; Messmer K Acta Anaesthesiol Scand Suppl; 1997; 111():256-8. PubMed ID: 9421036 [No Abstract] [Full Text] [Related]
5. Oxygen therapeutics: perfluorocarbons and blood substitute safety. Cohn CS; Cushing MM Crit Care Clin; 2009 Apr; 25(2):399-414, Table of Contents. PubMed ID: 19341916 [TBL] [Abstract][Full Text] [Related]
10. Resuscitation of dogs from endotoxic shock by continuous dextran infusion with and without perflubron added. Cain SM; Curtis SE; Vallet B; Bradley WE Adv Exp Med Biol; 1994; 345():235-42. PubMed ID: 7521564 [No Abstract] [Full Text] [Related]
11. [Fluosol-DA in extracorporeal circulation - an experimental study (author's transl)]. Ozono H; Taira A; Toyohira H; Higashi T; Yamashita M; Shimokawa S; Umebayashi Y; Saigenji H; Hamada Y; Arikawa K; Akita H Kyobu Geka; 1981 Oct; 34(10):776-80. PubMed ID: 7311221 [No Abstract] [Full Text] [Related]
13. [Development of acute exudative inflammation in rats upon perftoran infusion]. Lykova OF; Romanova TV; Moiseeva LM; Konysheva TV; Zorin NA Eksp Klin Farmakol; 2007; 70(1):60-2. PubMed ID: 17402596 [TBL] [Abstract][Full Text] [Related]
14. [Use of perfluorane in the transfusion therapy of tuberculosis and other bronchopulmonary diseases]. Zhilin IuN; Bakhmutova NV; Gamaev AE; Nabokova TS; Kaminskaia GO; Serebriannaia BA; Gus'kov MIu Probl Tuberk; 2000; (1):18-21. PubMed ID: 10750422 [TBL] [Abstract][Full Text] [Related]
15. [Research progress in estimating parameters of blood substitute function]. Xie J; Wang X Sheng Wu Yi Xue Gong Cheng Xue Za Zhi; 2009 Jun; 26(3):657-61. PubMed ID: 19634692 [TBL] [Abstract][Full Text] [Related]
16. The blockade of the reticuloendothelial system after the administration of perfluorocarbon artificial blood. Uchida T; Matsuda S; Kokubun K; Yoshida M; Satoh T; Kimura H; Kariyone S Nihon Ketsueki Gakkai Zasshi; 1986 Sep; 49(6):1222-7. PubMed ID: 3811785 [No Abstract] [Full Text] [Related]
18. [Results of the use of perftoran for anti-ischemic protection of renal transplant]. Zakharov VV Klin Khir; 1997; (1):24-6. PubMed ID: 9254261 [TBL] [Abstract][Full Text] [Related]
19. Control of plasma nitric oxide bioactivity by perfluorocarbons: physiological mechanisms and clinical implications. Rafikova O; Sokolova E; Rafikov R; Nudler E Circulation; 2004 Dec; 110(23):3573-80. PubMed ID: 15557364 [TBL] [Abstract][Full Text] [Related]
20. [Intraperitoneal perfusion of perftoran in the treatment of patients with diffuse purulent peritonitis]. Askerkhanov GR; Golubev AM; Guseĭnov AG; Moroz VV; Zagirov UZ Khirurgiia (Mosk); 2000; (9):8-10. PubMed ID: 11026193 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]